Eponyms in Oncology: Bence-Jones Protein
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
Most Blood Cancer Drug Trials Are Not Randomized, Use Surrogate Endpoints
Of more than 2500 trials analyzed, 21% were randomized. -
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes. -
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care. -
Current and Emerging Therapies for Relapsed and Refractory Multiple Myeloma
Experts review approved therapies and treatments still under investigation.
MULTIPLE MYELOMA NEWS
Frontline Daratumumab Improves Progression-Free Survival in High-Risk Multiple Myeloma
Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma
Risk of Neurologic AEs Lower With Immune Checkpoint Inhibitors Than With Other Cancer Therapies
Lenalidomide Maintenance Superior to Bortezomib for Myeloma Patients With Abn1q
Racial Disparities Noted in Treatment With Bone-Modifying Agents Among Patients With Multiple Myeloma
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
Loading... 
Loading...